SHP656, a polysialylated recombinant factor VIII (PSA‐rFVIII): First‐in‐human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A

Evaluation of factor VIII polysialylation: Identification of a longer-acting experimental therapy in mice and monkeys

(2019) Helmut Glantschnig et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A

(2016) S. W. Pipe et al.   BLOOD

Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients

(2016) B. Brand et al.   HAEMOPHILIA

Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products

(2016) Nadine Andersson et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A

(2015) B. A. Konkle et al.   BLOOD

Half-life extended factor VIII for the treatment of hemophilia A

(2015) A. Tiede   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Adjustment of endogenous concentrations in pharmacokinetic modeling

(2014) Alexander Bauer et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A

(2014) T. E. Coyle et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A

(2013) J. Mahlangu et al.   BLOOD

Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A

(2013) A. Tiede et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients

(2012) J. S. Powell et al.   BLOOD

Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight

(2011) S. Bjorkman et al.   BLOOD

A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management

(2011) L. A. VALENTINO et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A

(2008) P. W. COLLINS et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS